Ischemia–reperfusion injury
- 1 February 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Organ Transplantation
- Vol. 18 (1), 34-43
- https://doi.org/10.1097/mot.0b013e32835c2a05
Abstract
Organ transplantation and other major surgeries are impacted by ischemia-reperfusion injury (IRI). Mesenchymal stromal cells (MSCs) recently became an attractive alternative therapeutic tool to combat IRI. The present review highlights the effects of MSCs in the preclinical animal models of IRI and clinical trials, and explains their potential modes of action based on the pathophysiological IRI cascade. The application of MSCs in animal models of IRI show anti-inflammatory and anti-apoptotic effects, particularly for damage to the kidneys, heart and lungs. The mechanism of MSC action remains unclear, but may involve paracrine factors which could include the transfer of microvesicles, RNA or mitochondria. Although few clinical trials have reached completion, adverse effects appear minimal. MSCs show promise in protecting against IRI-induced damage. They appear to help recovery mainly by affecting the levels of inflammation and apoptosis during the organ repair process. In addition, they may mediate immunomodulatory effects on the innate and adaptive immune processes triggered during reperfusion and reduce fibrosis. Success in preclinical animal models has led to the initiation of ongoing clinical trials.Keywords
This publication has 101 references indexed in Scilit:
- Increased immunogenicity is an integral part of the heat shock response following renal ischemiaCell Stress and Chaperones, 2012
- Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial InfarctionJAMA, 2011
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- In vivo prevention of transplant arteriosclerosis by ex vivo–expanded human regulatory T cellsNature Medicine, 2010
- Mesenchymal stem cell therapy: Two steps forward, one step backTrends in Molecular Medicine, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2009
- Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In VivoCell, 2009
- Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophagesExperimental Hematology, 2009
- Early Beneficial Effects of Bone Marrow-Derived Mesenchymal Stem Cells Overexpressing Akt on Cardiac Metabolism After Myocardial InfarctionThe International Journal of Cell Cloning, 2009
- Prostaglandins PGE2 and PGI2 promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activationExperimental Cell Research, 2007